Thor Medical A EBIT per Share
The EBIT per Share of Thor Medical A (TRMED.OL) as of Aug 12, 2026 is -0.04 NOK. In the previous year, EBIT per Share was -2.74 NOK — a change of -98.49% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.04NOK
YoY
-98.49%
Last updated:
EBIT per Share of Thor Medical A is 2026 -0.04 NOK. EBIT per Share of Thor Medical A was 2025 -2.74 NOK. It decreases by -98.49% higher compared to the previous year.
Access this data via the Eulerpool API
Thor Medical A Stock analysis
What does Thor Medical A do? Nordic Nanovector ASA is a Norwegian biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of lymphoma and other cancers. The company was founded in 2009 by a group of leading scientists in the field of cancer research, focused on developing new and innovative treatment options for cancer.
Nordic Nanovector's business model is based on the use of antibodies specifically targeted to cancer cells. An example of this is the drug Betalutin, which contains a radioactive substance that selectively destroys cancer cells. Betalutin has been tested in multiple clinical trials and has shown promising results in the treatment of non-Hodgkin lymphoma.
In addition to Betalutin, the company also has another technology platform based on the use of antibodies with high affinity to specific types of cancer. Nordic Nanovector also manufactures a wide range of diagnostic tools that can be used in cancer research.
Since its inception, Nordic Nanovector has received numerous national and international awards and prizes for its innovative products and technologies. The company has established relationships with various academic institutions and organizations to advance research and development.
In addition to product development, the company has undergone an impressive capital raise to advance the development of these therapies. Nordic Nanovector has received several public and private financings in recent years to support and expand its research activities. In 2015, the company went public on the Oslo Stock Exchange, foregoing the conquest of the US market.
The foundation of the company's portfolio is protected by technology patents and product patents. The company has undergone several challenging development and approval steps to gain a competitive advantage over competitors. The goal is to promote long-term growth and availability of the products worldwide.
Nordic Nanovector believes that its business model is realized based on innovative technologies in cancer research. With a focus on the development of therapies and diagnostic tools, the company has built significant potential in the industry. The future prospects and growth outlook are positive and are expected to contribute to even greater success for Nordic Nanovector in the future. Thor Medical A is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Thor Medical A stock
EBIT per Share of Thor Medical A is -0.04 NOK in 2026.
EBIT per Share of Thor Medical A changed from -2.74 NOK to -0.04 NOK, representing a -98.49% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Thor Medical A since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Thor Medical A
All Key Metrics — Thor Medical A
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth